University of Maryland has identified proteolysis targeting chimeras (PROTACs) acting as apoptosis regulator Bcl-2, Bcl-2-like protein 1 (BCL2L1) and induced myeloid leukemia cell differentiation protein Mcl-1 degradation inducers.
Carrick Therapeutics UK Ltd. has synthesized cyclin-dependent kinase 12 (CDK12) and/or cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of autoimmune diseases, cardiovascular disorders, fragile X syndrome, muscular dystrophy, neurodegeneration, renal disorders and cancer.
Shanghai Leadopharma Technology Co. Ltd. has presented transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists reported to be useful for the treatment of irritable bowel syndrome, Crohn's disease, ulcerative colitis, pain and inflammation.
Scorpion Therapeutics Inc. has disclosed urea derivatives acting as phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.
University of Copenhagen has divulged 4-hydroxypyridine and 4-hydroxyquinoline derivatives acting as G-protein coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of fibrosis, diabetes, inflammatory and cognitive disorders.
Lead Discovery Center GmbH has described 3-substituted 1H-pyrrolo[2,3-b]-pyridines acting as G protein-coupled receptor kinase 5 (GRK5) inhibitors reported to be useful for the treatment of cancer, inflammatory, immunological, metabolic and cardiovascular disorders.
Sanofi SA has divulged substituted pyrrolo[2,3-d]pyrimidines acting as leucine-rich repeat kinase 2 (LRRK2; dardarin and/or G2019S mutant) inhibitors reported to be useful for the treatment of Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Lewy body dementia, progressive supranuclear palsy, frontotemporal dementia and Niemann-Pick disease.
Blueprint Medicines Corp. has identified substituted pyrimidinyl-pyrazoles acting as cyclin-dependent kinase (CDK) inhibitors, particularly CDK2, reported to be useful for the treatment of cancer.
Scripps Research has synthesized 3C-Like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19).
RSS
